MedPath

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

Early Phase 1
Completed
Conditions
NAFLD
Interventions
Dietary Supplement: homocysteine (Hcy) lowering supplements
Registration Number
NCT05720702
Lead Sponsor
Duke University
Brief Summary

The purpose of the study is to assess the feasibility of a trial to test the effects of homocysteine (Hcy) lowering supplements in patients with NAFLD.

NAFLD patients will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits to complete activities such as physical exam, fibroscan, blood draws, and questionnaires.

Detailed Description

The purpose of the study is to assess the feasibility of a trial to test the effects of homocysteine (Hcy) lowering supplements in patients with NAFLD.

NAFLD patients will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits. During the in person visits NAFLD participants will complete the following activities:

* Review medical history

* Physical examination

* Vital signs (blood pressure, heart rate, respiratory rate, body temperature)

* Measure height, weight, body mass index, and waist circumference

* Grip test

* Fasting blood tests

* Pregnancy test (if applicable)

* Fibroscan with CAP score

* QOL questionnaire

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
NAFLD Grouphomocysteine (Hcy) lowering supplementsThe NAFLD group will be asked to take Hcy lowering supplements (Vitamin B12, Folate, Vitamin B6, and Betaine) daily for 12 weeks. Over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits. During the in person visits NAFLD participants will complete the following activities: Review medical history; Physical examination; Vital signs (blood pressure, heart rate, respiratory rate, body temperature); Measure height, weight, body mass index, and waist circumference; Grip test; Fasting blood tests; Pregnancy test (if applicable); Fibroscan with CAP score; QOL questionnaire
Primary Outcome Measures
NameTimeMethod
FibroScan-aspartate aminotransferase (FAST) score12 weeks

To minimize interindividual variability of fibroscan measurements, all of the fibroscan will be performed by a single, experienced operator using the same probe (M vs. XL) and technique for the paired measurements. The FibroScan-aspartate aminotransferase (FAST) score is a simple algorithm that can diagnose NASH using an elevated (≥ 4) NAFLD activity score (NAS) and significant fibrosis score (≥ 2).

Secondary Outcome Measures
NameTimeMethod
Feasibility as measured by percentage of completion of enrollment4 months

The trial design will be considered feasible if at least 13 NAFLD patients (≥80%) are enrolled over the 4-month period

Assess safety of the trial.12 weeks

Based on reported adverse reactions.

Trial Locations

Locations (1)

Duke University

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath